Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus (“PEDV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.
1. A vaccine composition comprising an attenuated prototype passaged strain of PEDV, and a carrier, wherein said strain of PEDV is at least 95% identical, at a full length nucleotide level, to SEQ ID NO:67 and comprises a nucleic acid sequence which encodes:
a polyprotein 1a/1b with one or more substitutions at position 814, 1076, 1564, 1896, 2310, 2600, 3247, 3473, or 3522 as determined by reference to SEQ ID NO:52; and
a spike protein with one or more substitutions at position 257, 326, 375, 491, 881, 888, 1277, 1339, or 1358 as determined by reference to SEQ ID NO:54; and
an ORF3 protein truncated at position 39 or later as determined by reference to SEQ ID NO:55; and
an envelope protein with one or more substitutions at position 69 or 62 as determined by reference to SEQ ID NO:56; and
a membrane protein with a substitution at position 208 as determined by reference to SEQ ID NO: 57; and
a nucleocapsid protein with one or more substitutions at position 141, 418, 424, or 439 as determined by reference to SEQ ID NO: 58.
2. The vaccine composition of claim 1 wherein said strain of PEDV comprises one or more of the following substitutions or their conservative variants:
a V at position 814, A at position 1076, F at position 1564, I at position 1896, H at position 2310 Y at position 2600, F at position 3247, V at position 3473, or R at position 3522 of polyprotein 1a/1b as determined by reference to SEQ ID NO:52;
a N at position 257, I at position 326, F at position 375, Y at position 491, R at position 881, R at position 888 F at position 1277, T at position 1339, or L at position 1358 of spike protein as determined by reference to SEQ ID NO:54;
a truncation at position 39 or later of ORF 3 as determined by reference to SEQ ID NO:55;
a I at position 69 of envelope protein as determined by reference to SEQ ID NO:56;
a T at position 208 of membrane protein as determined by reference to SEQ ID NO: 57;
a L at position 141, Q at position 418, N at position 424, or I at position 439 nucleocapsid protein as determined by reference to SEQ ID NO: 58.
3. A vaccine composition comprising a live attenuated prototype porcine epidemic diarrhea virus (PEDV); and a carrier
wherein said composition is capable of protecting swine from challenge by both variant and prototype strains of PEDV and preventing or treating one or more symptoms associated with PEDV infection, and wherein achievement of protection is determined by an endpoint selected from the group consisting of prevention or control of any of the PEDV infection symptoms of dehydration, fever, diarrhea, vomiting, poor lactational performance, poor reproduction performance, mortality, and prevention or control of weight loss or failure to gain weight wherein the virus is the strain of claim 2 .
4. A method of preventing disease in healthy pigs caused by PEDV, comprising first vaccinating said pigs with a prototype attenuated live PEDV vaccine composition of claim 1 in 3 week old pigs followed by a second vaccination at week 7 or older pigs with a vaccine composition of a variant indel virus.
5. A vaccine composition according to claim 1 , wherein said strain of PEDV is at least 99% identical, at a full length nucleotide level, to SEQ ID NO:67.
6. A vaccine composition comprising an attenuated prototype passaged strain of PEDV, and a carrier, wherein said strain of PEDV is at least 95% identical, at a full length nucleotide level, to SEQ ID NO: 67 and comprises a nucleic acid sequence which encodes:
polyprotein 1a/1b comprising F at position 1564, I at position 1896, Y at position 2600, F at position 3247, and V at position 3473 as determined by reference to SEQ ID NO:52; and
spike protein comprising I at position 326, Y at position 491, R at position 888, F at position 1277, T at position 1339, or L at position 1358 as determined by reference to SEQ ID NO:54; and
ORF 3 truncated at position 39 or later as determined by reference to SEQ ID NO:55; and
envelope protein comprising I at position 69 of as determined by reference to SEQ ID NO:56; and
membrane protein comprising T at position 208 of as determined by reference to SEQ ID NO: 57; and
nucleocapsid protein comprising I position 439 of nucleocapsid protein as determined by reference to SEQ ID NO: 58.
7. The vaccine composition according to claim 6 , wherein said strain of PEDV is at least 99% identical, at a full length nucleotide level, to SEQ ID NO:67.
8. A vaccine composition comprising a live attenuated prototype porcine epidemic diarrhea virus (PEDV); and a carrier
wherein said composition is capable of protecting swine from challenge by both variant and prototype strains of PEDV and preventing or treating one or more symptoms associated with PEDV infection, and wherein achievement of protection is determined by an endpoint selected from the group consisting of prevention or control of any of the PEDV infection symptoms of dehydration, fever, diarrhea, vomiting, poor lactational performance, poor reproduction performance, mortality, and prevention or control of weight loss or failure to gain weight wherein the virus is the strain of claim 7 .
9. A method of preventing disease in healthy pigs caused by PEDV, comprising first vaccinating said pigs with a prototype attenuated live PEDV vaccine composition of claim 6 in 3 week old pigs followed by a second vaccination at week 7 or older pigs with a vaccine composition of a variant indel virus.